The global biotechnology reagents & kits market size was valued at USD 337.28 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 16.5% from 2021 to 2028. Increasing R&D expenditure by biotechnology companies, expanding applications of molecular biology, technological advancements in the field of biotechnology, and growing demand for synthetic biology are key driving factors for the growth of this market. The development of numerous diagnostic tests for COVID-19 has further driven market growth. Novel research has suggested the use of a flow cytometry-based method for COVID-19 testing. Researchers have also used the technique to explore the types of T cells involved in COVID-19 immune responses. This has resulted in high demand for flow cytometry reagents & kits, thereby augmenting the market growth.
With recent advancements in the molecular biology arena, several engineering tools and strategies were developed to cope with rising market demand. Expanding research base in molecular biology has driven the usage of biotechnology reagents & kits over the past few years. The field of genomic sequencing has also witnessed several technological advancements over the recent years since the inception of the first revolutionary DNA sequencing technique. In the past few years, there have been extraordinary developments in areas, including high-throughput sequencing, genome engineering, big-data analysis & storage, and gene therapy.
RT-PCR assay is the most widely used method for the detection of viral RNA in patient samples. Researchers have also developed specific assays to detect COVID-19. The Center for Disease Control (CDC) has developed a different test protocol by validation and comparison of several kits used in the extraction of nucleic acids. They also used alternative prime and probe sets to detect SARS-CoV-2 in clinical samples. Isolation of nucleic acids is an integral part of the COVID-19 testing workflow.
The huge demand for nucleic acid isolation and purification kits led to a global shortage of these kits in the initial phase of the pandemic. Leveraging this opportunity, several companies undertook various initiatives, such as the expansion of their production capabilities, distribution agreements, and new product launches, to enhance their market positions. This also accelerated the entry of new players into the market, thereby intensifying the market competition.
The detection kits segment dominated the market in 2020 with a revenue share of over 22%. This can be attributed to the widespread utilization of detection kits at various end-use settings, such as healthcare, industrial processing, food, and agriculture. With the growing need to curb the COVID-19 virus, the production of detection kits has increased over the past few months.
For instance, in May 2021, the Defence Research and Development Organisation’slaboratory, the Defence Institute of Physiology and Allied Sciences (DIPAS), introduced an antibody-dependent kit DIPCOVAN DIPAS-VDx SARS-CoV-2 IgG antibody Microwell ELISA for sero-surveillance. This kit can recognize both Spikes and Nucleocapsid (S&N) protein of coronavirus with 97% sensitivity and 99% specificity. The detection kit is manufactured in collaboration with Vanguard Diagnostics Private Limited.
Increasing demand for molecular diagnostics is a major factor contributing to the growth of amplification kits. Biotechnology and healthcare companies have increased the production of RT-PCR-based testing kits due to the rapid rise in the number of COVID-19 cases around the world. For instance, in January 2021, New England BioLab, Inc. launched the Luna SARS-CoV-2 RT-qPCR Assay Kit for the detection of SARS-CoV-2 nucleic acid.
Cell culture technology dominated the market with a revenue share of more than 24% in 2020 and is followed by Polymerase Chain Reaction (PCR) technology. Increasing demand for cell culture reagents by the research community is driving the segment growth. The comprehensive portfolio of cell culture media and reagents owned by companies has supplemented the market growth.
PCR is one of the key technologies used for the detection and analysis of specific gene sequences. Currently available real-time PCR assays offer high specificity and sensitivity, and are, thereby, considered the go-to methods for various genomic studies. Currently, the PCR technique is considered the most accurate, for the detection of COVID-19, leading to a significant increase in the adoption of PCR testing kits and reagents.
Next-Generation Sequencing (NGS) is now considered a reliable and powerful tool for the characterization of cell lines used for the production of gene therapy, vaccines, and recombinant proteins. Thus, with the advancements in sequencing techniques, the market for sequencing reagents is anticipated to witness significant growth over the forecast period.
The RNA segment accounted for the largest revenue share of over 29% owing to the increasing research on transcriptomics. Research on extracellular RNA for clinical diagnosis has increased over the past five years. Companies and universities are entering the field for the development of RNA-based therapeutics by the virtue of transcriptomic technologies. Key industry participants are constantly introducing new products to drive the market. For instance, in March 2021, PromegaCorp. launched XpressAmp Direct amplification reagent.
It enables RNA extraction-free sample preparation, which is automation-friendly. Such advancements are expected to drive market growth.DNA testing has significant application in newborn genetic screening, identity diagnostics & forensics, pharmacogenomics diagnostic testing, and drug metabolism, which is expected to drive the segment growth. Increasing demand for DNA diagnostics technology is the major driver of this segment.
The virus segment accounted for the highest revenue share of over 31% in 2020, which is closely followed by the bacteria segment. The dominance of the segment can be attributed to the increasing application of viruses in gene therapy and vaccinology. Increasing R&D to support the use of recombinant viral vectors in vaccine development further drives the segment.
Furthermore, the outbreak of SARS-COV-2 infection acts as a driving factor for the market as there is an increase in demand for viral reagents, which is propelling the segment growth. The rising number of SARS-CoV-2 cases has fueled the demand for tests and reagents for testing as well as research purposes, thereby driving developments in the segment.
The use of therapeutic bacteria has revolutionized cancer management by enabling addressing certain limitations associated with conventional cancer therapies like surgery, radiotherapy, chemotherapy, and immunotherapy. Bacteria alone have the potential to act as anticancer agents. Such factors are anticipated to boost the segment growth over the forecast period.
The on-site purposes segment led the market in 2020 with a revenue share of over 55%. The rising utilization of Point-of-Care (POC) testing has primarily driven the segment growth. Efficient and timely POC testing based on the availability of POC reagents has supplemented the segment growth.
On-site testing applications in the food and beverage industry also aided the market expansion. It includes microbiological on-site testing and enzymatic on-site testing. Microbiological on-site testing is used in the detection of viruses, bacteria, and molds in food. Enzymatic on-site testing is used in the measurement of constituents, such as acid or alcohol and sugar in foods. This test is essential when analyzing beverage and dairy products.
A broad variety of research reagents contribute to the growth of various fields in science and medicine. Laboratory reagents are employed in various assays and methodologies, such as to support Immunohistochemistry (IHC), cell culture, flow cytometry, cell selection, flow cytometry, protein purification, immunodepletion, and others. In vitro reagents are crucial in clinical chemistry and testing laboratories.
The healthcare sector dominated the market in 2020 with a revenue share of over 50%. The segment will retain the leading position throughout the forecast years owing to the ongoing clinical trials and research & development activities for clinical diagnostics. Moreover, a shift in preference toward molecular diagnostics and personalized medicine has increased mergers and collaborations for developing novel technology.
This has subsequently driven the demand for various advanced products in the healthcare sector. For instance, in March 2021, Roche and GenMark diagnostics entered into a merger agreement to introduce innovative technology to test a wide range of pathogens with one patient specimen. GenMark’sePlex platform provides quick and effective results.
The rising penetration of biotechnology tools to create traits of organisms including animals, plants, as well as microbes for yield, size, and color is propelling the market growth for the food & agriculture segment. Furthermore, the advancements in plant tissue culture techniques and recombinant DNA technology have drastically changed the agriculture sector leading to significant market growth.
North America dominated the global market with a revenue share of more than 37% in 2020. The presence of key players actively developing technologically advanced novel products coupled with the introduction of several new products by emerging start-ups has majorly contributed to the dominance of the region.
The U.S.-based players and organizations are continuously involved in high-quality life science research, thereby affecting ancillary markets. Various strategic initiatives by key companies to maintain regional presence and market share enhance the competition. For instance, in March 2021, Agilent technologies acquired Resolution Bioscience Inc., a liquid biopsy firm, to offer an NGS-based noninvasive liquid biopsy test platform, in turn, strengthening its genomics business.
Asia Pacific is anticipated to be the fastest-growing regional market over the forecast period. The growing disposable income, improving diagnostics & therapeutic infrastructure, and increasing research activities for the development of effective therapeutics are some key factors that have driven the market growth in Asia Pacific.
The market is expected to witness tremendous growth in the near future. A rise in the number of technological collaborations between operating entities coupled with their expanding product portfolio has intensified the market competition. The new product/technology developments undertaken by key companies positively affect the market growth and increase their competitiveness in the market. Biotechnology companies are actively responding to the outbreak of the COVID-19 pandemic. This has further created opportunities for players striving to gain a higher market share by capitalizing on untapped avenues. Some key players operating in the global biotechnology reagents & kits market include:
Thermo Fisher Scientific
New England Biolabs
Agilent Technologies, Inc.
F. Hoffmann-La Roche Ltd.
Takara Bio, Inc.
Toyobo Co. Ltd.
Market size value in 2021
USD 453.69 billion
Revenue forecast in 2028
USD 1,146.28 billion
CAGR of 16.5% from 2021 to 2028
Base year for estimation
2017 - 2019
2021 - 2028
Revenue in USD billion/trillion and CAGR from 2021 to 2028
Revenue forecast, company share, competitive landscape, growth factors, and trends
Kit type, technology, tested parameters, micro-organisms, purpose, end use, and region
North America; Europe; Asia Pacific; Latin America; Middle East Africa
U.S.; Canada; Germany; U.K.; Italy; France; Spain; China; India; Australia; Japan; Brazil; Mexico; South Africa; Saudi Arabia
Thermo Fisher Scientific; QIAGEN; New England Biolabs; Illumina, Inc.; Agilent Technologies, Inc.; Bio-Rad Laboratories; F. Hoffmann-La Roche Ltd.; Merck KGaA; Promega Corp.; Takara Bio, Inc.; LGC Ltd.; Toyobo Co. Ltd.
If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of the customization
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2028. For the purpose of this study, Grand View Research has segmented the global biotechnology reagents & kits market report on the basis of kit type, technology, tested parameters, micro-organisms, purpose, end use, and region:
Kit Type Outlook (Revenue, USD Billion, 2017 - 2028)
Technology Outlook (Revenue, USD Billion, 2017 - 2028)
Tested Parameters Outlook (Revenue, USD Billion, 2017 - 2028)
Micro-Organisms Outlook (Revenue, USD Billion, 2017 - 2028)
Purpose Outlook (Revenue, USD Billion, 2017 - 2028)
End-use Outlook (Revenue, USD Billion, 2017 - 2028)
Food & Agriculture
Natural Resources & Environment
Regional Outlook (Revenue, USD Billion, 2017 - 2028)
Middle East Africa (MEA)
b. Cell culture technology dominated the biotechnology reagents & kits market with a revenue share of more than 24% in 2020 and is followed by Polymerase Chain Reaction (PCR) technology.
b. The RNA segment accounted for the largest revenue share of over 29% owing to the increasing research on transcriptomic in the biotechnology reagents & kits market.
b. The virus segment accounted for the highest revenue share of over 31% in 2020, which is closely followed by the bacteria segment in the biotechnology reagents & kits market.
b. The on-site purposes segment led the biotechnology reagents & kits market in 2020 with a revenue share of over 55%.
b. The healthcare sector dominated the biotechnology reagents & kits market in 2020 with a revenue share of over 50%.
b. The global biotechnology reagents & kits market size was estimated at USD 337.28 billion in 2020 and is expected to reach USD 453.69 billion in 2021.
b. The global biotechnology reagents & kits market is expected to grow at a compound annual growth rate of 16.5% from 2021 to 2028 to reach USD 1,146.28 billion by 2028.
b. The detection kits segment dominated the biotechnology reagents & kits market in 2020 with a revenue share of over 22%.
b. Some key players operating in the biotechnology reagents & kits market include Thermo Fisher Scientific, QIAGEN, New England Biolabs, Illumina Inc., Agilent Technologies, Inc., Bio-Rad Laboratories, F. Hoffmann-La Roche Ltd., and Merck KGaA.
b. Key factors that are driving the biotechnology reagents & kits market growth include increasing R&D expenditure by biotechnology companies, expanding applications of molecular biology, technological advancements in the field of biotechnology, and growing demand for synthetic biology.
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
Leading SME award by D&B
"The quality of research they have done for us has been excellent."
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.
We value your investment and offer free customization with every report to fulfil your exact research needs.